Rongchang Biotech: The Phase I/IIa clinical trial of the company's independently developed and dual-specificity antibody drug conjugate RC288 as a monotherapy for locally advanced unresectable or metastatic solid tumors has been approved.
Rongchang Biotech announced that its independently developed bispecific antibody drug conjugate RC288 has been approved for Phase I/IIa clinical trials for the treatment of locally advanced unresectable or metastatic solid tumors.
Latest
6 m ago
